
ALEC
Healthcare · Biotechnology · $378.1M market cap
$2.54+0.09 (+3.7%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +119.5% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | -0.23 | 1.11 | +582.6% |
| Aug 6, 2026 | After the close | -0.24 | -0.21 | +12.5% |
| May 7, 2026 | After the close | -0.27 | -0.21 | +22.2% |
| Mar 3, 2026 | Time not confirmed | -0.39 | -0.34 | +13.1% |
| Nov 6, 2025 | After the close | -0.41 | -0.34 | +17.1% |
| Aug 7, 2025 | After the close | -0.45 | -0.30 | +33.3% |
| May 8, 2025 | After the close | -0.46 | -0.41 | +10.9% |
| Feb 25, 2025 | Before the open | -0.54 | -0.02 | +96.3% |
| Nov 6, 2024 | After the close | -0.53 | -0.43 | +18.9% |
| Aug 7, 2024 | After the close | -0.48 | -0.40 | +16.7% |
| May 8, 2024 | After the close | -0.49 | -0.38 | +22.4% |
| Feb 27, 2024 | After the close | -0.77 | -0.49 | +36.4% |
| Nov 7, 2023 | After the close | -0.65 | -0.53 |
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and…
| +18.5% |
| Aug 3, 2023 | After the close | -0.82 | 0.02 | +102.4% |
| May 4, 2023 | After the close | -0.78 | -0.55 | +29.5% |
| Feb 28, 2023 | After the close | -0.46 | -0.63 | -37.0% |
| Nov 8, 2022 | After the close | -0.51 | -0.56 | -9.8% |
| Aug 4, 2022 | After the close | -0.44 | 0.12 | +127.3% |
| May 5, 2022 | After the close | 0.17 | -0.54 | -417.6% |
| Feb 24, 2022 | After the close | -0.19 | -0.68 | -257.9% |
| Nov 4, 2021 | After the close | 2.83 | 1.49 | -47.3% |
| Aug 3, 2021 | After the close | -0.69 | -0.69 | 0.0% |
| May 5, 2021 | After the close | -0.67 | -0.66 | +1.5% |
| Feb 25, 2021 | After the close | -0.66 | -0.66 | 0.0% |
| Nov 10, 2020 | After the close | -0.55 | -0.67 | -21.8% |
| Aug 11, 2020 | After the close | -0.50 | -0.58 | -16.0% |
| May 13, 2020 | Before the open | -0.43 | -0.53 | -23.3% |
| Mar 24, 2020 | After the close | -0.44 | -0.45 | -2.3% |
| Nov 12, 2019 | After the close | -0.40 | -0.47 | -17.5% |
| Aug 12, 2019 | After the close | -0.32 | -0.36 | -12.5% |
| May 13, 2019 | After the close | -0.31 | -0.27 | +12.9% |
| Mar 26, 2019 | After the close | -0.28 | -1.48 | -428.6% |
| Oct 12, 2018 | Time not confirmed | — | -0.29 | — |